Share This Press Release
For Immediate Release
Sinai Hospital Successfully Treats First Prostate Patient in Maryland with CyberKnife
Now patients in Maryland diagnosed with prostate cancer,
have a new, nonsurgical treatment option. Staff at the Sinai Hospital CyberKnife
Center has successfully treated their first case of prostate cancer using this
stereotactic radiosurgery system.
"The accuracy of the CyberKnife allows for a
significantly reduced area of radiation in the normal tissue surrounding the
prostate,” said Keith O'Reilly, M.D., head of the Prostate
Cancer Program at the CyberKnife
Center. "By using larger doses of radiation over a shorter time
period, we are able to reduce the side effects compared to traditional
Sinai Hospital is the first medical center in Maryland
to use CyberKnife to treat prostate cancer. Prostate cancer is the leading
diagnosis of cancer in men affecting one out of six men in the United
States, and the second leading cause of death in men; the American Cancer
Society estimated that more than 234,000 new cases of prostate cancer were
diagnosed in 2006.
The CyberKnife radiation therapy system uses near
real-time tracking to locate the precise position of the tumor in the body. In
combination with the Synchrony® Respiratory Tracking System, a high-energy X-ray
source mounted on the robotic arm delivers extremely focused beams of radiation
to the tumor. This highly targeted technique allows the maximum amount of
radiation to be delivered to the tumor, while protecting surrounding healthy
tissue from damage.
Traditional treatment options for patients with
early-stage prostate cancer include surgery; external beam radiation; and
brachytherapy, which is radioactive seed implantation. With CyberKnife,
treatment is significantly shortened to five treatments over the course of a
week from a normally lengthy treatment course of 37 doses of traditional
external beam radiation given over nearly eight weeks.
The results of using CyberKnife to treat prostate cancer
have been well documented and are quite impressive. More than three years of
data, complied from varies CyberKnife centers across the country, have found
that with only five treatments with CyberKnife, PSA levels fall more rapidly and
there is a lower incidence of urinary, bowel and erectile side effects than with
traditional treatment options.
To help further refine and improve techniques and
outcomes with the treatment of prostate cancer, The Sinai CyberKnife Center is
participating in a national clinical trial with institutions, including the
Swedish Hospital of Seattle and Beth Israel in Boston.
"The continued growth of the CyberKnife Center reflects
Sinai Hospital's dedication to providing patients with a variety of highly
effective cutting-edge treatment options,” said Mark Brenner, M.D., chief of
Radiation Oncology at Sinai Hospital and medical director of the CyberKnife
The CyberKnife Center is part of theAlvin
& Lois Lapidus Cancer Institute, which offers cancer patients the most
advanced diagnosis and treatment for a wide range of cancers. Sinai Hospital and
Northwest Hospital's vision of coordinated, multidisciplinary oncology care
places the patient and family at the center of a coordinated set of services and
specialists who work on behalf of the patient.
Hospital is a member of LifeBridge Health, a
regional health organization that includes Northwest Hospital Center, Levindale Hebrew
Geriatric Center and Hospital, Jewish
Convalescent & Nursing Home, and related subsidiaries and
# # #